KHTR.F Stock Overview
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KHTR.F from our risk checks.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.27 |
| 52 Week High | CA$4.22 |
| 52 Week Low | CA$3.20 |
| Beta | 0.48 |
| 1 Month Change | 7.02% |
| 3 Month Change | 2.74% |
| 1 Year Change | 19.81% |
| 3 Year Change | 2.15% |
| 5 Year Change | -21.85% |
| Change since IPO | -22.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| KHTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.4% | -2.2% | -3.7% |
| 1Y | 19.8% | 11.6% | 20.5% |
Return vs Industry: KHTR.F exceeded the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: KHTR.F matched the US Market which returned 20.2% over the past year.
Price Volatility
| KHTR.F volatility | |
|---|---|
| KHTR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KHTR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KHTR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 725 | Samira Sakhia | www.gud-knight.com |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation.
Knight Therapeutics Inc. Fundamentals Summary
| KHTR.F fundamental statistics | |
|---|---|
| Market cap | US$422.83m |
| Earnings (TTM) | -US$12.19m |
| Revenue (TTM) | US$237.73m |
1.8x
P/S Ratio-35.2x
P/E RatioIs KHTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KHTR.F income statement (TTM) | |
|---|---|
| Revenue | CA$328.20m |
| Cost of Revenue | CA$175.55m |
| Gross Profit | CA$152.65m |
| Other Expenses | CA$169.49m |
| Earnings | -CA$16.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 46.51% |
| Net Profit Margin | -5.13% |
| Debt/Equity Ratio | 8.3% |
How did KHTR.F perform over the long term?
See historical performance and comparison